HRP20031090A2 - Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases - Google Patents
Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases Download PDFInfo
- Publication number
- HRP20031090A2 HRP20031090A2 HR20031090A HRP20031090A HRP20031090A2 HR P20031090 A2 HRP20031090 A2 HR P20031090A2 HR 20031090 A HR20031090 A HR 20031090A HR P20031090 A HRP20031090 A HR P20031090A HR P20031090 A2 HRP20031090 A2 HR P20031090A2
- Authority
- HR
- Croatia
- Prior art keywords
- mmol
- image
- compounds
- tert
- yield
- Prior art date
Links
- 230000004054 inflammatory process Effects 0.000 title claims description 6
- 208000026278 immune system disease Diseases 0.000 title claims description 5
- IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical class O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 99
- 239000003153 chemical reaction reagent Substances 0.000 claims description 44
- 238000002360 preparation method Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000010992 reflux Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 230000014759 maintenance of location Effects 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- -1 oxygen radicals Chemical class 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- QPKSDZYQGFDJIU-UHFFFAOYSA-N 4-tert-butylcyclohexane-1-carbonyl chloride Chemical compound CC(C)(C)C1CCC(C(Cl)=O)CC1 QPKSDZYQGFDJIU-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000012265 solid product Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 7
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 7
- QVQKEGYITJBHRQ-UHFFFAOYSA-N 4-tert-butylcyclohexane-1-carboxylic acid Chemical compound CC(C)(C)C1CCC(C(O)=O)CC1 QVQKEGYITJBHRQ-UHFFFAOYSA-N 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 7
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 7
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- 229960004132 diethyl ether Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 5
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 210000003622 mature neutrocyte Anatomy 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229960001701 chloroform Drugs 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000002895 emetic Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 229940052303 ethers for general anesthesia Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229950005741 rolipram Drugs 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- ARDGQYVTLGUJII-UHFFFAOYSA-N 2,2-dimethylpropanimidamide;hydrochloride Chemical compound Cl.CC(C)(C)C(N)=N ARDGQYVTLGUJII-UHFFFAOYSA-N 0.000 description 2
- WZVZUKROCHDMDT-UHFFFAOYSA-N 2-acetamidobutanoic acid Chemical compound CCC(C(O)=O)NC(C)=O WZVZUKROCHDMDT-UHFFFAOYSA-N 0.000 description 2
- XIZFRYIWRFNILW-UHFFFAOYSA-N 3-bromobenzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=CC(Br)=C1 XIZFRYIWRFNILW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BMMVPRZGPCWIQV-UHFFFAOYSA-N 4-tert-butyl-n-[1-(3-cyclopentyl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]cyclohexane-1-carboxamide Chemical compound N=1N=C(C2CCCC2)NC(=O)C=1C(CC)NC(=O)C1CCC(C(C)(C)C)CC1 BMMVPRZGPCWIQV-UHFFFAOYSA-N 0.000 description 2
- DAWLPDYNBDVOHV-UHFFFAOYSA-N 4-tert-butyl-n-[1-(3-cyclopropyl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]cyclohexane-1-carboxamide Chemical compound N=1N=C(C2CC2)NC(=O)C=1C(CC)NC(=O)C1CCC(C(C)(C)C)CC1 DAWLPDYNBDVOHV-UHFFFAOYSA-N 0.000 description 2
- NMGGKBQJHSJZDI-UHFFFAOYSA-N 6-(1-aminopropyl)-3-cyclopentyl-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1CCCC1 NMGGKBQJHSJZDI-UHFFFAOYSA-N 0.000 description 2
- OWLUXOZTCYRDQS-UHFFFAOYSA-N 6-(1-aminopropyl)-3-cyclopropyl-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1CC1 OWLUXOZTCYRDQS-UHFFFAOYSA-N 0.000 description 2
- PLMBEEQJNFICMG-UHFFFAOYSA-N 6-(1-aminopropyl)-3-tert-butyl-2h-1,2,4-triazin-5-one Chemical compound CCC(N)C1=NN=C(C(C)(C)C)NC1=O PLMBEEQJNFICMG-UHFFFAOYSA-N 0.000 description 2
- MJTCPHAQLNKPMZ-UHFFFAOYSA-N 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound N12N=C(C=3C=CC=CC=3)NC(=O)C2=C(CC)N=C1C1CCC(C(C)(C)C)CC1 MJTCPHAQLNKPMZ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008578 acute process Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 description 2
- JRYOZJIRAVZGMV-UHFFFAOYSA-N cyclopropanecarboximidamide;hydron;chloride Chemical compound Cl.NC(=N)C1CC1 JRYOZJIRAVZGMV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- BDWPSOYWGDZETD-UHFFFAOYSA-N n-[1-(3-tert-butyl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]acetamide Chemical compound CC(=O)NC(CC)C1=NN=C(C(C)(C)C)NC1=O BDWPSOYWGDZETD-UHFFFAOYSA-N 0.000 description 2
- IMGTUMIAOYMTIG-UHFFFAOYSA-N n-[1-[3-(4-bromophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=C(Br)C=C1 IMGTUMIAOYMTIG-UHFFFAOYSA-N 0.000 description 2
- YJMNOKOLADGBKA-UHFFFAOYSA-N naphthalene-1-carbonitrile Chemical compound C1=CC=C2C(C#N)=CC=CC2=C1 YJMNOKOLADGBKA-UHFFFAOYSA-N 0.000 description 2
- OXDWHBYEKLTZHO-UHFFFAOYSA-N naphthalene-1-carboximidamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C(=N)N)=CC=CC2=C1 OXDWHBYEKLTZHO-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QVQKEGYITJBHRQ-KYZUINATSA-N trans-4-tert-butylcyclohexanecarboxylic acid Chemical compound CC(C)(C)[C@H]1CC[C@H](C(O)=O)CC1 QVQKEGYITJBHRQ-KYZUINATSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- NIHUZJPITMUICY-UHFFFAOYSA-N 1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound O=C1NC=NN2C=NC=C12 NIHUZJPITMUICY-UHFFFAOYSA-N 0.000 description 1
- FTFZJGRXFCKEIU-UHFFFAOYSA-N 2-(3-bromophenyl)-7-(4-tert-butylcyclohexyl)-5-ethyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound N12N=C(C=3C=C(Br)C=CC=3)NC(=O)C2=C(CC)N=C1C1CCC(C(C)(C)C)CC1 FTFZJGRXFCKEIU-UHFFFAOYSA-N 0.000 description 1
- AHOXBKMPMGVYCK-UHFFFAOYSA-N 2-(4-oxo-3h-imidazo[4,5-d]triazin-2-yl)benzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1N1NC(=O)C2=NC=NC2=N1 AHOXBKMPMGVYCK-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- RRULRSLJNLFGNK-UHFFFAOYSA-N 2-bromobenzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=CC=C1Br RRULRSLJNLFGNK-UHFFFAOYSA-N 0.000 description 1
- YQQHMYAEQTYRKO-UHFFFAOYSA-N 2-phenyl-3h-imidazo[4,5-d]triazin-4-one Chemical class N1=C2N=CN=C2C(=O)NN1C1=CC=CC=C1 YQQHMYAEQTYRKO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ZFJCIAUNANWWCB-UHFFFAOYSA-N 2-tert-butyl-7-(4-tert-butylcyclohexyl)-5-ethyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound N12N=C(C(C)(C)C)NC(=O)C2=C(CC)N=C1C1CCC(C(C)(C)C)CC1 ZFJCIAUNANWWCB-UHFFFAOYSA-N 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- KWDHABCUIIRLJP-UHFFFAOYSA-N 3-chlorobenzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=CC(Cl)=C1 KWDHABCUIIRLJP-UHFFFAOYSA-N 0.000 description 1
- UIISHESBWIBGED-UHFFFAOYSA-N 3-cyanobenzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=CC(C#N)=C1 UIISHESBWIBGED-UHFFFAOYSA-N 0.000 description 1
- GYLKKXHEIIFTJH-UHFFFAOYSA-N 3-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC(C#N)=C1 GYLKKXHEIIFTJH-UHFFFAOYSA-N 0.000 description 1
- KISQHILAOJSVET-UHFFFAOYSA-N 3-fluorobenzenecarboximidamide;hydron;chloride Chemical compound Cl.NC(=N)C1=CC=CC(F)=C1 KISQHILAOJSVET-UHFFFAOYSA-N 0.000 description 1
- DKNQVJWYIUJWNC-UHFFFAOYSA-N 3-nitrobenzenecarboximidamide;hydrochloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC([N+]([O-])=O)=C1 DKNQVJWYIUJWNC-UHFFFAOYSA-N 0.000 description 1
- RUSAWEHOGCWOPG-UHFFFAOYSA-N 3-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC(C#N)=C1 RUSAWEHOGCWOPG-UHFFFAOYSA-N 0.000 description 1
- IMTHEBSPHHMJOJ-UHFFFAOYSA-N 4-bromobenzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=C(Br)C=C1 IMTHEBSPHHMJOJ-UHFFFAOYSA-N 0.000 description 1
- JQDATBKJKUWNGA-UHFFFAOYSA-N 4-fluorobenzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=C(F)C=C1 JQDATBKJKUWNGA-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- NKJIFDNZPGLLSH-UHFFFAOYSA-N 4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1 NKJIFDNZPGLLSH-UHFFFAOYSA-N 0.000 description 1
- SBIGYTCANPNGIF-UHFFFAOYSA-N 4-tert-butyl-n-[1-(3-tert-butyl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]cyclohexane-1-carboxamide Chemical compound N=1N=C(C(C)(C)C)NC(=O)C=1C(CC)NC(=O)C1CCC(C(C)(C)C)CC1 SBIGYTCANPNGIF-UHFFFAOYSA-N 0.000 description 1
- FAAHFEDEXZTGQQ-UHFFFAOYSA-N 4-tert-butyl-n-[1-(5-oxo-3-phenyl-2h-1,2,4-triazin-6-yl)propyl]cyclohexane-1-carboxamide Chemical compound N=1N=C(C=2C=CC=CC=2)NC(=O)C=1C(CC)NC(=O)C1CCC(C(C)(C)C)CC1 FAAHFEDEXZTGQQ-UHFFFAOYSA-N 0.000 description 1
- LRKIVWCJNUHYKS-UHFFFAOYSA-N 4-tert-butyl-n-[1-[3-(4-methylphenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]cyclohexane-1-carboxamide Chemical compound N=1N=C(C=2C=CC(C)=CC=2)NC(=O)C=1C(CC)NC(=O)C1CCC(C(C)(C)C)CC1 LRKIVWCJNUHYKS-UHFFFAOYSA-N 0.000 description 1
- VSRBVNWZVJVALL-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(2-bromophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC=C1Br VSRBVNWZVJVALL-UHFFFAOYSA-N 0.000 description 1
- GDOZNHHADHRVJX-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(3-bromophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC(Br)=C1 GDOZNHHADHRVJX-UHFFFAOYSA-N 0.000 description 1
- GBQHCVUEJUSYPG-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(3-chlorophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC(Cl)=C1 GBQHCVUEJUSYPG-UHFFFAOYSA-N 0.000 description 1
- JKUWMHIELIUJKG-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(3-fluorophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC(F)=C1 JKUWMHIELIUJKG-UHFFFAOYSA-N 0.000 description 1
- ZUZHFKLADFQQKZ-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(3-nitrophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC([N+]([O-])=O)=C1 ZUZHFKLADFQQKZ-UHFFFAOYSA-N 0.000 description 1
- IZOGZKLGXUAJLE-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(4-bromophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=C(Br)C=C1 IZOGZKLGXUAJLE-UHFFFAOYSA-N 0.000 description 1
- XEXYJEWMMPNAIS-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(4-fluorophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=C(F)C=C1 XEXYJEWMMPNAIS-UHFFFAOYSA-N 0.000 description 1
- XWWDFLUZSSMRMR-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(4-methylphenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=C(C)C=C1 XWWDFLUZSSMRMR-UHFFFAOYSA-N 0.000 description 1
- GHTRHCFYRUFWPM-UHFFFAOYSA-N 6-(1-aminopropyl)-3-(4-nitrophenyl)-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=C([N+]([O-])=O)C=C1 GHTRHCFYRUFWPM-UHFFFAOYSA-N 0.000 description 1
- BYRFUHZAWIQONZ-UHFFFAOYSA-N 6-(1-aminopropyl)-3-cyclohexyl-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1CCCCC1 BYRFUHZAWIQONZ-UHFFFAOYSA-N 0.000 description 1
- MSPNQDQVZKJNDN-UHFFFAOYSA-N 6-(1-aminopropyl)-3-naphthalen-1-yl-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC2=CC=CC=C12 MSPNQDQVZKJNDN-UHFFFAOYSA-N 0.000 description 1
- LHDZVBXHCJKGRV-UHFFFAOYSA-N 6-(1-aminopropyl)-3-phenyl-2h-1,2,4-triazin-5-one Chemical compound N1C(=O)C(C(N)CC)=NN=C1C1=CC=CC=C1 LHDZVBXHCJKGRV-UHFFFAOYSA-N 0.000 description 1
- HMHFEYRLZYOLNY-UHFFFAOYSA-N 7-(4-tert-butylcyclohexyl)-1h-imidazo[4,5-d]triazin-4-one Chemical class C1CC(C(C)(C)C)CCC1N1C(N=NNC2=O)=C2N=C1 HMHFEYRLZYOLNY-UHFFFAOYSA-N 0.000 description 1
- YKFMNLNYBRPHPX-UHFFFAOYSA-N 7-(4-tert-butylcyclohexyl)-2-cyclopentyl-5-ethyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound N12N=C(C3CCCC3)NC(=O)C2=C(CC)N=C1C1CCC(C(C)(C)C)CC1 YKFMNLNYBRPHPX-UHFFFAOYSA-N 0.000 description 1
- RRNVUBNJKXBZGT-UHFFFAOYSA-N 7-(4-tert-butylcyclohexyl)-2-cyclopropyl-5-ethyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound N12N=C(C3CC3)NC(=O)C2=C(CC)N=C1C1CCC(C(C)(C)C)CC1 RRNVUBNJKXBZGT-UHFFFAOYSA-N 0.000 description 1
- ZOLVYQHCUJFLBW-UHFFFAOYSA-N 7-(4-tert-butylcyclohexyl)-5-ethyl-2-(3-fluorophenyl)-1h-imidazo[5,1-f][1,2,4]triazin-4-one Chemical compound N12N=C(C=3C=C(F)C=CC=3)NC(=O)C2=C(CC)N=C1C1CCC(C(C)(C)C)CC1 ZOLVYQHCUJFLBW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- GWTCZUZCEZDCCN-KDURUIRLSA-N N12N=C(C=3C4=CC=CC=C4C=CC=3)NC(=O)C2=C(CC)N=C1[C@H]1CC[C@@H](C(C)(C)C)CC1 Chemical compound N12N=C(C=3C4=CC=CC=C4C=CC=3)NC(=O)C2=C(CC)N=C1[C@H]1CC[C@@H](C(C)(C)C)CC1 GWTCZUZCEZDCCN-KDURUIRLSA-N 0.000 description 1
- GRLHPWKAVKFVDE-HDICACEKSA-N N12N=C(C=3C=CC(C)=CC=3)NC(=O)C2=C(CC)N=C1[C@H]1CC[C@@H](C(C)(C)C)CC1 Chemical compound N12N=C(C=3C=CC(C)=CC=3)NC(=O)C2=C(CC)N=C1[C@H]1CC[C@@H](C(C)(C)C)CC1 GRLHPWKAVKFVDE-HDICACEKSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- BHPRVKQAJPDQLV-UHFFFAOYSA-N ethyl 3-acetamido-2-oxopentanoate Chemical compound CCOC(=O)C(=O)C(CC)NC(C)=O BHPRVKQAJPDQLV-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MTDUPZAXNYELOU-UHFFFAOYSA-N hydron;4-methylbenzenecarboximidamide;chloride Chemical compound Cl.CC1=CC=C(C(N)=N)C=C1 MTDUPZAXNYELOU-UHFFFAOYSA-N 0.000 description 1
- CJXJAUKCHHAJQN-UHFFFAOYSA-N hydron;4-nitrobenzenecarboximidamide;chloride Chemical compound Cl.NC(=N)C1=CC=C([N+]([O-])=O)C=C1 CJXJAUKCHHAJQN-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- RTBCNWZLMYNEML-UHFFFAOYSA-N n-[1-(3-cyclohexyl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1CCCCC1 RTBCNWZLMYNEML-UHFFFAOYSA-N 0.000 description 1
- CPCXBXTWWDRTIB-UHFFFAOYSA-N n-[1-(3-cyclopropyl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1CC1 CPCXBXTWWDRTIB-UHFFFAOYSA-N 0.000 description 1
- GCPXGXKWMATCPJ-UHFFFAOYSA-N n-[1-(3-naphthalen-1-yl-5-oxo-2h-1,2,4-triazin-6-yl)propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC2=CC=CC=C12 GCPXGXKWMATCPJ-UHFFFAOYSA-N 0.000 description 1
- YXRGHGIKMBKAKN-UHFFFAOYSA-N n-[1-(5-oxo-3-phenyl-2h-1,2,4-triazin-6-yl)propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC=C1 YXRGHGIKMBKAKN-UHFFFAOYSA-N 0.000 description 1
- FJPYYMXOIFVNPS-UHFFFAOYSA-N n-[1-[3-(2-bromophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC=C1Br FJPYYMXOIFVNPS-UHFFFAOYSA-N 0.000 description 1
- QPSZSSROJXKFPJ-UHFFFAOYSA-N n-[1-[3-(3-bromophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC(Br)=C1 QPSZSSROJXKFPJ-UHFFFAOYSA-N 0.000 description 1
- NICREEJQDGUZNR-UHFFFAOYSA-N n-[1-[3-(3-chlorophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC(Cl)=C1 NICREEJQDGUZNR-UHFFFAOYSA-N 0.000 description 1
- IQZAQHBELLJHLH-UHFFFAOYSA-N n-[1-[3-(3-cyanophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC(C#N)=C1 IQZAQHBELLJHLH-UHFFFAOYSA-N 0.000 description 1
- CVWPXFIILIPGKC-UHFFFAOYSA-N n-[1-[3-(3-fluorophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC(F)=C1 CVWPXFIILIPGKC-UHFFFAOYSA-N 0.000 description 1
- MSJSWBKLSBYEFR-UHFFFAOYSA-N n-[1-[3-(3-nitrophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=CC([N+]([O-])=O)=C1 MSJSWBKLSBYEFR-UHFFFAOYSA-N 0.000 description 1
- HGWKGQKVJWLVJZ-UHFFFAOYSA-N n-[1-[3-(4-fluorophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=C(F)C=C1 HGWKGQKVJWLVJZ-UHFFFAOYSA-N 0.000 description 1
- SMIMVWAPJUAOIK-UHFFFAOYSA-N n-[1-[3-(4-methylphenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=C(C)C=C1 SMIMVWAPJUAOIK-UHFFFAOYSA-N 0.000 description 1
- RITXWRKNUOOALH-UHFFFAOYSA-N n-[1-[3-(4-nitrophenyl)-5-oxo-2h-1,2,4-triazin-6-yl]propyl]acetamide Chemical compound N1C(=O)C(C(NC(C)=O)CC)=NN=C1C1=CC=C([N+]([O-])=O)C=C1 RITXWRKNUOOALH-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000706 no observed effect level Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0113344.6A GB0113344D0 (en) | 2001-06-01 | 2001-06-01 | Novel heterocycles 3 |
PCT/EP2002/005436 WO2002098879A1 (en) | 2001-06-01 | 2002-05-17 | Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20031090A2 true HRP20031090A2 (en) | 2005-08-31 |
Family
ID=9915717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20031090A HRP20031090A2 (en) | 2001-06-01 | 2003-12-29 | Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases |
Country Status (28)
Country | Link |
---|---|
US (2) | US7115602B2 (hu) |
EP (1) | EP1399447A1 (hu) |
JP (1) | JP2004536078A (hu) |
KR (1) | KR20040023605A (hu) |
CN (1) | CN1512993A (hu) |
BG (1) | BG108381A (hu) |
BR (1) | BR0210910A (hu) |
CA (1) | CA2449095A1 (hu) |
CO (1) | CO5540381A2 (hu) |
CZ (1) | CZ295609B6 (hu) |
EC (1) | ECSP034872A (hu) |
EE (1) | EE200300570A (hu) |
GB (1) | GB0113344D0 (hu) |
GT (1) | GT200200099A (hu) |
HR (1) | HRP20031090A2 (hu) |
HU (1) | HUP0400773A3 (hu) |
MX (1) | MXPA03010985A (hu) |
NO (1) | NO20035324D0 (hu) |
NZ (1) | NZ529848A (hu) |
PE (1) | PE20030231A1 (hu) |
PL (1) | PL366906A1 (hu) |
RU (1) | RU2003138078A (hu) |
SK (1) | SK14672003A3 (hu) |
SV (1) | SV2003001061A (hu) |
UA (1) | UA75149C2 (hu) |
UY (1) | UY27312A1 (hu) |
WO (1) | WO2002098879A1 (hu) |
ZA (1) | ZA200309111B (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2388111A (en) * | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
GB2388594A (en) * | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
FR2850653A1 (fr) * | 2003-02-04 | 2004-08-06 | Univ Pasteur | Derives de pyrazolotriazine, procede de preparation et utilisations |
JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
TW200745106A (en) * | 2005-10-03 | 2007-12-16 | Astrazeneca Ab | Chemical compounds |
WO2012123406A1 (en) | 2011-03-17 | 2012-09-20 | Algiax Pharmaceuticals Gmbh | Novel use of imidazotriazinones |
WO2013156231A1 (en) * | 2012-04-16 | 2013-10-24 | Algiax Pharmaceuticals Gmbh | Use of imidazotriazinones in neuropathic pain |
WO2015144598A1 (en) * | 2014-03-28 | 2015-10-01 | Algiax Pharmaceuticals Gmbh | Treatment of cognitive disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791025A (fr) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
GB1457873A (en) | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
DK109578A (da) | 1977-03-25 | 1978-09-26 | Allen & Hanburys Ltd | Fremgangsmaade til fremstilling af heterocycliske forbindelser |
AU738675B2 (en) * | 1997-11-12 | 2001-09-20 | Bayer Intellectual Property Gmbh | 2-phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors |
DE19827640A1 (de) * | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
CA2323008C (en) * | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Pharmaceutically active compounds |
-
2001
- 2001-06-01 GB GBGB0113344.6A patent/GB0113344D0/en not_active Ceased
-
2002
- 2002-05-17 EE EEP200300570A patent/EE200300570A/xx unknown
- 2002-05-17 WO PCT/EP2002/005436 patent/WO2002098879A1/en active IP Right Grant
- 2002-05-17 PL PL02366906A patent/PL366906A1/xx not_active Application Discontinuation
- 2002-05-17 MX MXPA03010985A patent/MXPA03010985A/es unknown
- 2002-05-17 HU HU0400773A patent/HUP0400773A3/hu unknown
- 2002-05-17 RU RU2003138078/04A patent/RU2003138078A/ru not_active Application Discontinuation
- 2002-05-17 CZ CZ20033275A patent/CZ295609B6/cs not_active IP Right Cessation
- 2002-05-17 NZ NZ529848A patent/NZ529848A/en unknown
- 2002-05-17 JP JP2003502000A patent/JP2004536078A/ja active Pending
- 2002-05-17 UA UA20031213199A patent/UA75149C2/uk unknown
- 2002-05-17 SK SK1467-2003A patent/SK14672003A3/sk unknown
- 2002-05-17 EP EP02743040A patent/EP1399447A1/en not_active Withdrawn
- 2002-05-17 KR KR10-2003-7015526A patent/KR20040023605A/ko not_active Application Discontinuation
- 2002-05-17 BR BR0210910-7A patent/BR0210910A/pt not_active IP Right Cessation
- 2002-05-17 CA CA002449095A patent/CA2449095A1/en not_active Abandoned
- 2002-05-17 CN CNA028110528A patent/CN1512993A/zh active Pending
- 2002-05-28 UY UY27312A patent/UY27312A1/es not_active Application Discontinuation
- 2002-05-29 GT GT200200099A patent/GT200200099A/es unknown
- 2002-05-30 US US10/160,352 patent/US7115602B2/en not_active Expired - Fee Related
- 2002-05-31 PE PE2002000464A patent/PE20030231A1/es not_active Application Discontinuation
- 2002-05-31 SV SV2002001061A patent/SV2003001061A/es not_active Application Discontinuation
-
2003
- 2003-11-24 BG BG108381A patent/BG108381A/bg unknown
- 2003-11-24 ZA ZA200309111A patent/ZA200309111B/en unknown
- 2003-11-28 NO NO20035324A patent/NO20035324D0/no not_active Application Discontinuation
- 2003-12-01 EC EC2003004872A patent/ECSP034872A/es unknown
- 2003-12-10 CO CO03108302A patent/CO5540381A2/es not_active Application Discontinuation
- 2003-12-29 HR HR20031090A patent/HRP20031090A2/hr not_active Application Discontinuation
-
2004
- 2004-10-12 US US10/964,380 patent/US20050065153A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL366906A1 (en) | 2005-02-07 |
US20030139415A1 (en) | 2003-07-24 |
KR20040023605A (ko) | 2004-03-18 |
JP2004536078A (ja) | 2004-12-02 |
NZ529848A (en) | 2006-02-24 |
CA2449095A1 (en) | 2002-12-12 |
ECSP034872A (es) | 2004-01-28 |
RU2003138078A (ru) | 2005-05-27 |
US20050065153A1 (en) | 2005-03-24 |
ZA200309111B (en) | 2004-11-24 |
PE20030231A1 (es) | 2003-05-16 |
CO5540381A2 (es) | 2005-07-29 |
BG108381A (bg) | 2004-11-30 |
HUP0400773A3 (en) | 2007-09-28 |
SV2003001061A (es) | 2003-03-18 |
EE200300570A (et) | 2004-04-15 |
MXPA03010985A (es) | 2004-10-28 |
SK14672003A3 (sk) | 2004-08-03 |
NO20035324L (no) | 2003-11-28 |
CN1512993A (zh) | 2004-07-14 |
HUP0400773A2 (hu) | 2004-07-28 |
CZ20033275A3 (en) | 2004-03-17 |
NO20035324D0 (no) | 2003-11-28 |
GB0113344D0 (en) | 2001-07-25 |
EP1399447A1 (en) | 2004-03-24 |
WO2002098879A1 (en) | 2002-12-12 |
BR0210910A (pt) | 2004-06-08 |
UY27312A1 (es) | 2003-02-28 |
GT200200099A (es) | 2003-02-13 |
CZ295609B6 (cs) | 2005-08-17 |
US7115602B2 (en) | 2006-10-03 |
UA75149C2 (en) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101647802A (zh) | 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶及其组合物 | |
KR20110037962A (ko) | 2-플루오로-N-메틸-4-[7-(퀴놀린-6-일-메틸)-이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 염 및 이의 제조 방법 | |
MX2007001759A (es) | Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos. | |
KR20140037858A (ko) | N-[(1h-피라졸-1-일)아릴]-1h-인돌 또는 1h-인다졸-3-카르복스아미드의 유도체, 이의 제조 및 p2y12 길항제로서의 이의 용도 | |
EP1506198A1 (en) | 5-ethylimidarotriazones | |
HRP20031090A2 (en) | Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases | |
EP1397363B1 (en) | 5-ethyl-imidazotriazinones | |
JP2005531550A (ja) | ホスホジエステラーゼ阻害剤としての5−エチル−イミダゾ(5,1−f)(1,2,4)トリアジン−4(3h)−オン | |
EP1399439B1 (en) | 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | |
AU2002344351A1 (en) | Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases | |
US20040254187A1 (en) | 5-ethyl-imidazotriazinones | |
EP1504008A1 (en) | 7-aminoimidazotriazones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20060428 Year of fee payment: 5 |
|
OBST | Application withdrawn |